Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
7.924
Zitationen
26
Autoren
2012
Jahr
Abstract
Antibody-mediated blockade of PD-L1 induced durable tumor regression (objective response rate of 6 to 17%) and prolonged stabilization of disease (rates of 12 to 41% at 24 weeks) in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer. (Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT00729664.).
Ähnliche Arbeiten
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 · 30.895 Zit.
AJCC Cancer Staging Manual
2016 · 17.399 Zit.
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 · 15.272 Zit.
The blockade of immune checkpoints in cancer immunotherapy
2012 · 13.521 Zit.
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
2012 · 12.500 Zit.
Autoren
- Julie R. Brahmer
- Scott S. Tykodi
- Laura Q.M. Chow
- Wen-Jen Hwu
- Suzanne L. Topalian
- Patrick Hwu
- Charles G. Drake
- Luis H. Camacho
- John Kauh
- Kunle Odunsi
- Henry C. Pitot
- Omid Hamid
- Shailender Bhatia
- Renato Martins
- Keith D. Eaton
- Shuming Chen
- Theresa M. Salay
- Suresh Alaparthy
- Joseph F. Grosso
- Alan J. Korman
- Susan Parker
- Shruti Agrawal
- S. Goldberg
- Drew M. Pardoll
- Ashok Gupta
- Jon M. Wigginton
Institutionen
- Johns Hopkins University(US)
- Sidney Kimmel Comprehensive Cancer Center(US)
- Fred Hutch Cancer Center(US)
- Cancer Research Center(US)
- Seattle Cancer Care Alliance(US)
- The University of Texas MD Anderson Cancer Center(US)
- St. Luke's Episcopal Hospital(US)
- Emory University(US)
- Cancer Institute (WIA)(IN)
- Roswell Park Comprehensive Cancer Center(US)
- Mayo Clinic(US)
- Angeles Clinic and Research Institute(US)
- Bristol-Myers Squibb (United States)(US)
- Bristol-Myers Squibb (Germany)(DE)